이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis (ASCEND in SPMS)

2017년 8월 10일 업데이트: Biogen

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension

This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).

Part 1: The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS).

The secondary objectives of Part 1 of this study are to determine the proportion of participants with consistent improvement in Timed 25-Foot Walk (T25FW), the change in participant-reported ambulatory status as measured by the 12-item MS Walking Scale (MSWS-12), the change in manual ability based on the ABILHAND Questionnaire, the impact of natalizumab on participant-reported quality of life using the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical), the change in whole brain volume between the end of study and Week 24 using magnetic resonance imaging (MRI) and the proportion of participants experiencing progression of disability as measured by individual physical Expanded Disability Status Scale (EDSS) system scores.

Part 2: The primary objective of Part 2 of the study is to evaluate the safety profile of natalizumab in participants with SPMS.

The secondary objectives of Part 2 of the study are to investigate long-term disability (based on clinical or participant-reported assessments) in participants with SPMS receiving natalizumab treatment for approximately 4 years and to assess change in brain volume and T2 lesion volume.

연구 개요

상태

종료됨

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

889

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 네덜란드
      • Amsterdam, 네덜란드, 1081 HV
        • Research Site
      • Breda, 네덜란드, 4800 RK
        • Research Site
      • Hertogenbosch, 네덜란드, 5223 GZ
        • Research Site
      • Hoorn, 네덜란드, 1624 NP
        • Research Site
      • Nieuwegein, 네덜란드, 3430 EM
        • Research Site
      • Sittard-Geleen, 네덜란드, 6130 MB
        • Research Site
  • 덴마크
      • Arthus C, 덴마크, 8000
        • Research Site
      • Esbjerg, 덴마크, 6700
        • Research Site
      • Glostrup, 덴마크, 2600
        • Research Site
      • København Ø, 덴마크, 2100
        • Research Site
      • Odense, 덴마크, 5000
        • Research Site
  • 독일
    • Baden Wuerttemberg
      • Bad Wilbad, Baden Wuerttemberg, 독일, 75323
        • Research Site
      • Tuebingen, Baden Wuerttemberg, 독일, 72076
        • Research Site
    • Baden-Wuerttemberg
      • Bad Mergentheim, Baden-Wuerttemberg, 독일, 97980
        • Research Site
    • Bayern
      • Muenchen, Bayern, 독일, 81675
        • Research Site
      • Muenchen, Bayern, 독일, 81377
        • Research Site
    • Brandenburg
      • Hennigsdorf, Brandenburg, 독일, 16761
        • Research Site
      • Teupitz, Brandenburg, 독일, 15755
        • Research Site
    • Hessen
      • Kassel, Hessen, 독일, 34121
        • Research Site
    • Nordrhein Westfalen
      • Duesseldorf, Nordrhein Westfalen, 독일, 40225
        • Research Site
      • Muenster, Nordrhein Westfalen, 독일, 48149
        • Research Site
    • Sachsen
      • Dresden, Sachsen, 독일, 01307
        • Research Site
  • 러시아 연방
      • Belgorod, 러시아 연방, 308007
        • Research Site
      • Kazan, 러시아 연방, 420021
        • Research Site
      • Kazan, 러시아 연방, 420097
        • Research Site
      • Moscow, 러시아 연방, 127015
        • Research Site
      • St. Petersburg, 러시아 연방, 197110
        • Research Site
      • Tyumen, 러시아 연방, 625000
        • Research Site
  • 미국
    • Arizona
      • Phoenix, Arizona, 미국, 85013
        • Research Site
      • Tucson, Arizona, 미국, 85741
        • Research Site
    • California
      • Fullerton, California, 미국, 92835
        • Research Site
      • Los Angeles, California, 미국, 90027
        • Research Site
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • Research Site
    • Florida
      • Tampa, Florida, 미국, 33612
        • Research Site
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • Research Site
      • Lake Barrington, Illinois, 미국, 60010
        • Research Site
      • Peoria, Illinois, 미국, 61606
        • Research Site
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • Research Site
      • Indianapolis, Indiana, 미국, 46256
        • Research Site
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • Research Site
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • Research Site
      • Lexington, Kentucky, 미국, 40513
        • Research Site
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • Research Site
    • Massachusetts
      • Burlington, Massachusetts, 미국, 01805
        • Research Site
    • Nebraska
      • Omaha, Nebraska, 미국, 68198
        • Research Site
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • Research Site
    • New Jersey
      • Teaneck, New Jersey, 미국, 07666
        • Research Site
    • New York
      • Latham, New York, 미국, 12110
        • Research Site
      • New York, New York, 미국, 10029
        • Research Site
    • North Carolina
      • Advance, North Carolina, 미국, 27006
        • Research Site
      • Charlotte, North Carolina, 미국, 28207
        • Research Site
      • Raleigh, North Carolina, 미국, 27607
        • Research Site
    • Ohio
      • Akron, Ohio, 미국, 44320
        • Research Site
      • Uniontown, Ohio, 미국, 44685
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • Research Site
    • Oregon
      • Clackamas, Oregon, 미국, 97015
        • Research Site
      • Portland, Oregon, 미국, 97239
        • Research Site
      • Portland, Oregon, 미국, 97225
        • Research Site
    • Tennessee
      • Nashville, Tennessee, 미국, 37215
        • Research Site
    • Virginia
      • Charlottesville, Virginia, 미국, 22903
        • Research Site
    • Washington
      • Seattle, Washington, 미국, 98101
        • Research Site
    • Wisconsin
      • Green Bay, Wisconsin, 미국, 54311
        • Research Site
      • Milwaukee, Wisconsin, 미국, 53215
        • Research Site
  • 벨기에
      • La Louviere, 벨기에, 7100
        • Research Site
      • Melsbroek, 벨기에, 1820
        • Research Site
      • Overpelt, 벨기에, 3900
        • Research Site
  • 스웨덴
      • Göteborg, 스웨덴, 41345
        • Research Site
      • Stockholm, 스웨덴, 17176
        • Research Site
      • Stockholm, 스웨덴, 14186
        • Research Site
      • Stockholm, 스웨덴, 18288
        • Research Site
      • Umeå, 스웨덴, 90185
        • Research Site
      • Örebro, 스웨덴, 70185
        • Research Site
  • 스페인
      • Barcelona, 스페인, 08035
        • Research Site
      • Barcelona, 스페인, 08036
        • Research Site
      • Barcelona, 스페인, 08041
        • Research Site
      • El Palmar, 스페인, 30120
        • Research Site
      • Madrid, 스페인, 28034
        • Research Site
      • Madrid, 스페인, 28040
        • Research Site
      • Majadahonda, 스페인, 28222
        • Research Site
      • Málaga, 스페인, 29010
        • Research Site
      • Santa Cruz de Tenerife, 스페인, 38010
        • Research Site
      • Sevilla, 스페인, 41009
        • Research Site
  • 아일랜드
      • Dublin, 아일랜드, D4
        • Research Site
      • Dublin, 아일랜드, D9
        • Research Site
  • 영국
      • Brighton, 영국, BN2 5BE
        • Research Site
      • London, 영국, WC1N 3BG
        • Research Site
      • Sheffield, 영국, S10 2JF
        • Research Site
    • Ayrshire
      • Irvine, Ayrshire, 영국, KA12 8SS
        • Research Site
    • Birmingham
      • Edgbaston, Birmingham, 영국, B15 2TH
        • Research Site
    • Devon
      • Exeter, Devon, 영국, EX2 5DW
        • Research Site
      • Plymouth, Devon, 영국, PL6 8BX
        • Research Site
    • Greater London
      • London, Greater London, 영국, SE5 9RS
        • Research Site
      • London, Greater London, 영국, E1 2AT
        • Research Site
    • London
      • Hammersmith, London, 영국, W6 8RF
        • Research Site
    • Lothian Region
      • Edinburgh, Lothian Region, 영국, EH4 2XU
        • Research Site
    • Manchester
      • Salford, Manchester, 영국, M6 8HD
        • Research Site
    • Merseyside
      • Liverpool, Merseyside, 영국, L9 7LJ
        • Research Site
    • Norfolk
      • Norwich, Norfolk, 영국, NR4 7UY
        • Research Site
    • Nottinghamshire
      • Nottingham, Nottinghamshire, 영국, NG7 2UH
        • Research Site
    • Swansea
      • Morriston, Swansea, 영국, SA6 6NL
        • Research Site
    • Tyne
      • Newcastle, Tyne, 영국, NE1 4LP
        • Research Site
  • 이스라엘
      • Jerusalem, 이스라엘, 91120
        • Research Site
      • Ramat Gan, 이스라엘, 52621
        • Research Site
  • 이탈리아
      • Bari, 이탈리아, 70124
        • Research Site
      • Florence, 이탈리아, 50134
        • Research Site
      • Genova, 이탈리아, 16132
        • Research Site
      • Milano, 이탈리아, 20122
        • Research Site
      • Milano, 이탈리아, 20132
        • Research Site
      • Naples, 이탈리아, 80138
        • Research Site
      • Napoli, 이탈리아, 80131
        • Research Site
      • Palermo, 이탈리아, 90146
        • Research Site
      • Pavia, 이탈리아, 27100
        • Research Site
      • Rome, 이탈리아, 00189
        • Research Site
      • Rome, 이탈리아, 00176
        • Research Site
    • Modena
      • Baggiovara, Modena, 이탈리아, 41100
        • Research Site
    • Palermo
      • Cefalu, Palermo, 이탈리아, 90015
        • Research Site
    • Varese
      • Gallarate, Varese, 이탈리아, 21013
        • Research Site
  • 체코
      • Brno, 체코, 65691
        • Research Site
      • Olomouc, 체코, 77520
        • Research Site
      • Praha, 체코, 12111
        • Research Site
    • Bohemia
      • Hradec Kralove, Bohemia, 체코, 50005
        • Research Site
  • 캐나다
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 2T9
        • Research Site
      • Edmonton, Alberta, 캐나다, T6G 2G3
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6T 1Z3
        • Research Site
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3H 4K4
        • Research Site
    • Ontario
      • Kingston, Ontario, 캐나다, K7L 2V7
        • Research Site
      • London, Ontario, 캐나다, N6A 5A5
        • Research Site
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • Research Site
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Research Site
    • Quebec
      • Gatineau, Quebec, 캐나다, J9J 0A5
        • Research Site
      • Greenfield Park, Quebec, 캐나다, J4V 2J2
        • Research Site
      • Montreal, Quebec, 캐나다, H2L 4M1
        • Research Site
      • Montreal, Quebec, 캐나다, H3A 2B4
        • Research Site
  • 폴란드
      • Bialystok, 폴란드, 15-276
        • Research Site
      • Gdansk, 폴란드, 80-803
        • Research Site
      • Katowice, 폴란드, 40-749
        • Research Site
      • Katowice, 폴란드, 40-595
        • Research Site
      • Katowice, 폴란드, 40-635
        • Research Site
      • Krakow, 폴란드, 31-505
        • Research Site
      • Lodz, 폴란드, 90-324
        • Research Site
      • Lublin, 폴란드, 20-954
        • Research Site
      • Olsztyn, 폴란드, 10-561
        • Research Site
      • Plewiska, 폴란드, 62-064
        • Research Site
      • Poznan, 폴란드, 61-853
        • Research Site
      • Szczecin, 폴란드, 70-111
        • Research Site
      • Warszawa, 폴란드, 04-141
        • Research Site
      • Warszawa, 폴란드, 02-097
        • Research Site
      • Warszawa, 폴란드, 01-697
        • Research Site
      • Warszawa-Miedzylesie, 폴란드, 04-749
        • Research Site
      • Wroclaw, 폴란드, 50-556
        • Research Site
  • 프랑스
      • Bordeaux, 프랑스, 33076
        • Research Site
    • Alpes Maritimes
      • Nice, Alpes Maritimes, 프랑스, 06002
        • Research Site
    • Bouches-du-Rhône
      • Marseille cedex 5, Bouches-du-Rhône, 프랑스, 13385
        • Research Site
    • Loire Atlantique
      • Nantes, Loire Atlantique, 프랑스, 44093
        • Research Site
    • Meurthe et Moselle
      • Nancy, Meurthe et Moselle, 프랑스, 54035
        • Research Site
    • Nord
      • Lille Cedex, Nord, 프랑스, 59000
        • Research Site
    • Rhone
      • Bron cedex, Rhone, 프랑스, 69677
        • Research Site
    • Somme
      • Salouel, Somme, 프랑스, 80054
        • Research Site
  • 핀란드
      • Jyväskylä, 핀란드, 40620
        • Research Site
      • Tampere, 핀란드, 33520
        • Research Site
      • Turku, 핀란드, 20520
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria (Part 1):

  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations.
  • SPMS defined as relapsing-remitting disease followed by progression of disability independent of or not explained by multiple sclerosis (MS) relapses for at least 2 years.
  • EDSS score of 3.0 to 6.5, inclusive.
  • Multiple Sclerosis Severity Score of 4 or higher.
  • Documented confirmed evidence of disease progression independent of clinical relapses over the 1 year prior to enrollment as defined in the Study Reference Guide.

Key Exclusion Criteria (Part 1):

  • Relapsing remitting multiple sclerosis (RRMS) or primary progressive MS as defined by the revised McDonald Committee criteria.
  • Clinical relapse (within 3 months) prior to randomization.
  • T25FW test of >30 seconds during the screening period.
  • Any value below the lower limit of normal for blood levels of leukocytes, lymphocytes, or neutrophils.
  • Considered by the Investigator to be immunocompromised based on medical history, physical examination, laboratory testing, or any other testing required by local guidelines, or due to prior immunosuppressive or immunomodulating treatment.
  • Subjects for whom MRI is contraindicated (i.e., have pacemakers or other contraindicated implanted metal devices, are allergic to gadolinium, or have claustrophobia that cannot be medically managed).
  • History of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (other than MS), dermatologic, psychiatric, and renal, or other major disease that would preclude participation in a clinical study.
  • History of malignant disease, including solid tumors and hematologic malignancies (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
  • Known history of or positive test result for human immunodeficiency virus.
  • Positive test result for hepatitis C virus (test for hepatitis C virus antibody or hepatitis B virus (test for hepatitis B surface antigen and/or hepatitis B core antibody).
  • History of transplantation or any anti-rejection therapy.
  • Presence of any infectious disease (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to screening.
  • History of progressive multifocal leukoencephalopathy or other opportunistic infections.

Treatment History (Part 1)

  • Any prior treatment with cell-depleting therapies, including total lymphoid irradiation, cladribine, rituximab, alemtuzumab, or bone marrow ablation.
  • Any prior treatment with natalizumab.
  • Treatment with mitoxantrone, cyclophosphamide, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, T cell or T cell receptor vaccination, fingolimod, daclizumab, or cytapheresis within 6 months prior to randomization.
  • Treatment with intravenous or oral corticosteroids, intravenous immunoglobulin, or plasmapheresis for treatment of MS within the 3 months prior to randomization.
  • Treatment with glatiramer acetate or any interferon beta preparations within 4 weeks prior to randomization.
  • Treatment with 4-aminopyridine within 30 days prior to randomization, unless a stable dose has been maintained for at least 30 days prior to randomization and will be continued for the course of this study.

Key Inclusion Criteria (Part 2):

  • Subjects must have participated in and completed Part 1 per protocol, and have documented assessment attempts for EDSS, T25FW, and 9HPT prior to first open-label dosing.

Key Exclusion Criteria (Part 2):

  • Subjects with any significant change in clinical status, including laboratory tests that, in the opinion of the Investigator, would make them unsuitable to participate in this extension study. The Investigator must re-review the subject's medical fitness for participation and consider any diseases that would preclude treatment.
  • Subjects who discontinued study treatment in Part 1 OR had fewer than 20 infusions in Part 1 OR missed 2 or more consecutive infusions in Part 1.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: natalizumab
In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
의약품: 나탈리주맙
치료군에 명시된 대로 투여
다른 이름들:
  • 티사브리
  • BG00002
실험적: Placebo
In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
의약품: 나탈리주맙
치료군에 명시된 대로 투여
다른 이름들:
  • 티사브리
  • BG00002
의약품: Placebo
Matched placebo in part 1

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Part 1: Percentage of Participants With Confirmed Progression of Disability in One or More of the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), or 9-Hole Peg Test (9HPT)
기간: Up to 96 weeks (2 years)

Confirmed disability progression, defined as ≥1 of the following criteria (confirmed at a second visit ≥6 months later and at Week 96):

  • Confirmed progression in EDSS (EDSS score increased from baseline [BL] by ≥1 point if BL EDSS ≤5.5 or by ≥0.5 points if BL EDSS ≥6);
  • Confirmed progression in T25FW (T25FW increased by ≥20% of the BL walk);
  • Confirmed progression in 9HPT (9HPT increased by ≥20% of the time taken at BL on either hand and confirmed on the same hand).

The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. The 95% confidence interval (CI) of the percentage is based on normal approximation.
Up to 96 weeks (2 years)
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: 218 weeks
AE: any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, placed the participant at immediate risk of death (a life-threatening event); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect. An SAE may have also been any other medically important event in the opinion of the Investigator.
218 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Part 1: Percentage of Participants With a T25FW Response
기간: Up to 96 weeks
T25FW response is defined as any improvement from the best pre-dose T25FW in at least 75% of the scheduled on-treatment visits through Week 96. The T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately administered again by having the patient walk back the same distance. The score for the T25FW is the average of the 2 completed trials. The 95% CI of the percentage is based on normal approximation.
Up to 96 weeks
Part 1: Change From Baseline in the 12-Item MS Walking Scale (MSWS-12)
기간: Baseline and Week 96
MSWS-12 is a participant self-assessment of the walking limitations due to MS during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where higher scores indicate greater impact on walking. A negative number on change from BL value indicates an improvement in MSWS-12.
Baseline and Week 96
Part 1: Change From Baseline in Manual Ability Score Based on the ABILHAND Questionnaire
기간: Baseline and Week 96
The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. The participant completes a 56-item questionnaire by estimating their own difficulty or ease in performing each of 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability. A positive number on change from baseline value indicates an improvement in ABILHAND.
Baseline and Week 96
Part 1: Change From Baseline in the Multiple Sclerosis Impact Scale-29 Physical (MSIS-29 Physical) Score
기간: Baseline and Week 96
The 29-item MSIS-29 is a participant-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a participant's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.
Baseline and Week 96
Part 1: Percentage Change From Week 24 in Whole Brain Volume at Week 96
기간: Week 24 and Week 96
Whole brain volume as measured by MRI.
Week 24 and Week 96
Part 1: Percentage of Participants Defined as Confirmed Progressors on EDSS Functional System Scores
기간: Up to 96 weeks

The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who met one of the following criteria:

  • an increase of ≥ 1 point from baseline system score of ≥ 1 or an increase of ≥ 2 points from baseline system score of 0 in at least 2 physical functional systems, or
  • an increase of ≥ 2 points from baseline system score of ≥ 1 or an increase of ≥ 3 points from baseline system score of 0 in any 1 physical functional system.

A confirmed progressor was defined as a participant who met the criteria for disability progression at any given visit and at the 6-Month Confirmation Visit. The 95% CIs are based on normal approximation.
Up to 96 weeks
Part 2: Percentage of Participants With Disability Worsening at 156 Weeks
기간: Week 156
Percentage of participants with disability worsening at each scheduled efficacy visit in Part 2, defined as one or more of the following: • ≥ 20% worsening from Part 1 baseline in T25FW; • ≥ 20% worsening from Part 1 baseline in 9HPT; • Worsening from Part 1 baseline in EDSS (≥ 1 point increase if Part 1 baseline EDSS ≤ 5.5 or ≥ 0.5 point increase if Part 1 baseline EDSS > 5.5). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. 95% CIs of percentages are based on normal approximation.
Week 156
Part 2: Absolute Change From Baseline (Part 1) in T25FW
기간: Baseline (Part 1) and Weeks 156, 204
The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Lower scores on time taken to reach 25 foot mark reflect a better outcome. Values are presented for the overall group, as well as the Confirmed Progressor (CP, defined in the primary outcome measure description above) and Non-Progressor (NP) subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in T25FW
기간: Baseline (Part 1) and Weeks 156, 204
The T25FW is a quantitative mobility and leg function performance test based on a timed 25-foot walk. The participant is directed to one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely. The time is calculated from the initiation of the instruction to start and ends when the participant has reached the 25-foot mark. The task is immediately repeated; the score for the T25FW is the average of the two completed trials. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Dominant Hand)
기간: Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Dominant Hand)
기간: Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)
기간: Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in 9HPT (Non-Dominant Hand)
기간: Baseline (Part 1) and Weeks 156, 204
The 9HPT is a brief, standardized, quantitative test of upper extremity function. The participant picks up 9 pegs puts them in a block containing nine empty holes, and, once they are in the holes, removes them again as quickly as possible one at a time. The total time to complete the task is recorded. Two consecutive trials with the dominant hand are immediately followed by two consecutive trials with the non-dominant hand. The two trials for each hand are averaged. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in EDSS
기간: Baseline (Part 1) and Weeks 156, 204
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Percentage Change From Baseline (Part 1) in EDSS
기간: Baseline (Part 1) and Weeks 156, 204
The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Values are presented for the overall group, as well as the CP (defined in the primary outcome measure description above) and NP subgroups.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in the 6-Minute Walk Test (6MWT)
기간: Baseline (Part 1) and Weeks 156 and 204
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Baseline (Part 1) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 1) in the 6MWT
기간: Baseline (Part 1) and Weeks 156, 204
The 6MWT measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in the MSIS-29 Physical Score
기간: Baseline (Part 1) and Weeks 156 and 204
The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.
Baseline (Part 1) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 1) in the MSIS-29 Physical Score
기간: Baseline (Part 1) and Weeks 156, 204
The 29-item MSIS-29 is a patient-reported outcome measure to assess the impact of MS on day-to-day life during the past 2 weeks from a patient's perspective; it measures 20 physical items and 9 psychological items. The physical score is generated by summing individual items and then transforming to a scale with a range of 0 to 100, where high scores indicate worse health. A negative number on change from baseline value indicates an improvement in MSIS-29.
Baseline (Part 1) and Weeks 156, 204
Part 2: Absolute Change From Baseline (Part 1) in the Symbol Digit Modalities Test (SDMT)
기간: Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
Part 2: Percentage Change From Baseline (Part 1) in the SDMT
기간: Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
SDMT is a screening test for cognitive impairment. Participants are given 90 seconds in which to pair specific numbers with given geometric figures using a key. Scores range from 0 to 110 (best).
Baseline (Part 1) and every 4 weeks from Week 108 to Week 204
Part 2: Absolute Change From Baseline (Part 2) in the Work Productivity and Activity Impairment - Multiple Sclerosis (WPAI-MS) Questionnaire
기간: Part 2 Baseline (Week 108) and Weeks 156 and 204
The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Part 2 Baseline (Week 108) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 2) in the WPAI-MS Questionnaire
기간: Part 2 Baseline (Week 108) and Weeks 156 and 204
The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (percentage of work time missed) 2. Presenteesism (percentage of impairment at work/reduced on-the-job effectiveness) 3. Work productivity loss (WPL; percentage of overall work impairment [absenteeism plus presenteeism]) 4. Activity Impairment (AI; percentage of overall activity impairment). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
Part 2 Baseline (Week 108) and Weeks 156 and 204
Part 2: Percentage Change From Week 24 (Part 1) in Whole Brain Volume
기간: Week 24 (Part 1) and Weeks 156 and 204
Whole brain volume as measured by MRI.
Week 24 (Part 1) and Weeks 156 and 204
Part 2: Percentage Change From Baseline (Part 1) in Whole Gray Matter Brain Volume
기간: Baseline (Part 1) and Weeks 156 and 204
Whole grey matter brain volume as measured by MRI.
Baseline (Part 1) and Weeks 156 and 204
Part 2: Summary of New/Enlarging T2 Lesion Counts
기간: Baseline (Part 1) up to Week 204
New or enlarging T2 lesions as measured by MRI.
Baseline (Part 1) up to Week 204
Part 2: Percentage Change From Baseline (Part 1) in Number of New/Enlarging T2 Lesions
기간: Baseline (Part 1) and Weeks 156 and 204
New or enlarging T2 lesions as measured by MRI.
Baseline (Part 1) and Weeks 156 and 204

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Biogen

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2011년 9월 13일

기본 완료 (실제)

2015년 7월 28일

연구 완료 (실제)

2016년 4월 13일

연구 등록 날짜

최초 제출

2011년 7월 21일

QC 기준을 충족하는 최초 제출

2011년 8월 11일

처음 게시됨 (추정)

2011년 8월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 9월 11일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 8월 10일

마지막으로 확인됨

2017년 8월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 101MS326
  • 2010-021978-11 (EudraCT 번호)

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

속발성 진행성 다발성 경화증에 대한 임상 시험

나탈리주맙에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Gambia

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

구독하다